Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.
Saved in:
| Title: | Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma. |
|---|---|
| Authors: | Monberg TJ; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark., Pakola SA; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland., Albieri B; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark., Ellebaek E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark., Donia M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark., Eefsen RL; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark., Borch TH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland., Lorentzen T; Department of Gastroenterology, Copenhagen University Hospital, 2730 Herlev, Denmark., Hendel HW; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, 2730 Herlev, Denmark., Vestergaard C; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark., Lorentzen C; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark., Holmstroem RB; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland., Khammari A; Nantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, 44000 Nantes, France., Kistler C; TILT Biotherapeutics Ltd, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, Helsinki, Finland., Westergaard MCW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark., Met Ö; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark; Department of Health Technology, Technical University of Denmark, 2800 Lyngby, Denmark., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, Helsinki, Finland., Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, Helsinki, Finland., Sorsa S; TILT Biotherapeutics Ltd, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, Helsinki, Finland., Dreno B; Nantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, 44000 Nantes, France., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Progam, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, Helsinki, Finland; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. Electronic address: akseli.hemminki@helsinki.fi., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark. Electronic address: inge.marie.svane@regionh.dk. |
| Source: | Cell reports. Medicine [Cell Rep Med] 2025 Mar 18; Vol. 6 (3), pp. 102016. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
